The Financial Benefits of Faster Development Times: Integrated Formulation Development, Real-Time Manufacturing, and Clinical Testing

2020 ◽  
Vol 54 (6) ◽  
pp. 1453-1460
Author(s):  
Joseph A. DiMasi ◽  
Michael Wilkinson
2018 ◽  
Vol 23 (06) ◽  
pp. 294-294
Author(s):  
Cornelia Fietz

DiMasi JA et al. Assessing the Financial Benefits of Faster Development Times: The Case of Single-source Versus Multi-vendor Outsourced Biopharmaceutical Manufacturing. Clin Ther 2018; 40: 963–972 Die Entwicklung neuer Arzneimittel ist sehr zeit- und kostenaufwändig. Zudem birgt sie ein hohes Risiko, da schlussendlich nur wenige Substanzen die Marktzulassung erlangen. Sponsoren ist daher an einer Verkürzung der Forschungs- und Entwicklungszeit gelegen, um Entwicklungskosten einzusparen und früher Gewinne mit dem Produkt zu erzielen. Die Autoren vergleichen dazu Gesamtanbieter mit Multi-Lieferanten der Biopharma-Produktion.


2017 ◽  
Vol 148 (4) ◽  
pp. 296-307
Author(s):  
Cristiane M Ida ◽  
Malinda L Butz ◽  
Robert B Jenkins ◽  
Jann N Sarkaria ◽  
Gaspar J Kitange ◽  
...  

Abstract Objectives To develop and evaluate a real-time methylation-specific polymerase chain reaction (RT-MSP) MGMT assay, with a particular focus on small biopsies and indeterminate testing results. Methods We assessed formalin-fixed paraffin-embedded glioblastoma or gliosarcoma specimens (n = 641). A test-validation group (n = 51) with previously obtained reference laboratory (RL) results was used to determine performance characteristics of the RT-MSP assay. An indeterminate (equivocal) category was established for cases that could not be clearly classified as positive or negative. Results Overall agreement of RT-MSP and RL results was 91% (41/45 nonindeterminate cases). Discordant cases were tested by pyrosequencing, and results were most concordant with RT-MSP. Among cases with limited amounts of tissue (n = 7), six yielded valid results by RT-MSP (all negative); the single invalid result consisted of a stereotactic biopsy specimen obtained 14 years prior. A subset of indeterminate cases obtained during clinical testing (n = 18/575 [3%]) was also evaluated by pyrosequencing and showed a heterogeneous pattern of methylation across the eight interrogated CpG sites. Conclusions The RT-MSP assay that we developed in-house is a robust clinical detection method for the heterogeneous process of MGMT promoter methylation in glioblastoma.


2014 ◽  
Vol 2014 ◽  
pp. 1-12 ◽  
Author(s):  
Susan D’Souza

This review summarizes the methods used to study real-time (37°C) drug release from nanoparticulate drug delivery systems and establish an IVIVC. Since no compendial standards exist, drug release is currently assessed using a variety of methods including sample and separate (SS), continuous flow (CF), dialysis membrane (DM) methods, and a combination thereof, as well as novel techniques like voltametry and turbidimetry. This review describes the principle of each method along with their advantages and disadvantages, including challenges with set-up and sampling. The SS method allows direct measurement of drug release with simple set-up requirements, but sampling is cumbersome. With the CF method, sampling is straightforward but the set-up is time consuming. Set-up as well as sampling is easier with the DM, but it may not be suitable for drugs that bind to the membrane. Novel methods offer the possibility of real-time drug release measurement but may be restricted to certain types of drugs. Of these methods, Level A IVIVCs have been obtained with dialysis, alone or in combination with the sample and separate technique. Future efforts should focus on developing mathematical models that describe drug release mechanisms as well as facilitate formulation development of nano-sized dosage forms.


2011 ◽  
Vol 22 (2) ◽  
pp. 358-363 ◽  
Author(s):  
Isabelle Berg ◽  
Anja Palmowski-Wolfe ◽  
Katja Schwenzer-Zimmerer ◽  
Cornelia Kober ◽  
Ernst-Wilhelm Radue ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document